RIPK1 and neoplasm: Previous mouse models have shown that activation of TRAIL can lead to the activation of RIPK1, thereby inducing inflammatory responses [82] and driving cell death [83], explaining the anti-tumor role of CXCL11+ TAMs by eliminating tumor cells through TNFSF10-RIPK1.